Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $52.30B | 40x | 0.74 | $837.02 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.4% Upside | Upgrade to Pro+ | |
| Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $48.33B | 39.5x | -0.28 | $68.24 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.2% Upside | Upgrade to Pro+ | |
| BeOne Medicines DRC | NASDAQ | Healthcare | Biotechnology & Medical Research | $34.38B | 121.1x | 0.85 | $315.51 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.7% Upside | Upgrade to Pro+ | |
| Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | $32.15B | -23.1x | 1.68 | $148.50 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.2% Upside | Upgrade to Pro+ | |
| Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | $29.65B | -25x | 0.38 | $149.54 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.8% Upside | Upgrade to Pro+ | |
| IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | $29.42B | 22.5x | 4.61 | $178.64 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.3% Upside | Upgrade to Pro+ | |
| BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | $25.20B | -17.9x | 0.27 | $99.66 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.9% Upside | Upgrade to Pro+ | |
| WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $19.65B | 25.1x | 0.57 | $4.60 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Wuxi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $19.65B | 25.1x | 0.57 | $9.61 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $17.84B | 18.8x | -1.5 | $29.13 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
| Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $16.17B | -11.2x | 0.04 | $21.12 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $15.44B | -54.2x | -1.35 | $242.60 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.5% Upside | Upgrade to Pro+ | |
| Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.91B | 34.3x | 1.57 | $521.33 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.9% Downside | Upgrade to Pro+ | |
| Regencell Bioscience Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.89B | -4,125x | $29.30 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| Ionis Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.59B | -31.9x | -1.55 | $76.26 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
| Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.79B | -40x | -1.01 | $514 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
| Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | $11.53B | 15.9x | 0.26 | $44.36 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.4% Upside | Upgrade to Pro+ | |
| Abivax ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.70B | -21.4x | 0.35 | $120 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.9% Upside | Upgrade to Pro+ | |
| Arrowhead Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.66B | 46.7x | 0.36 | $68.90 | 3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
| Praxis Precision | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.37B | -24.8x | 1 | $335.88 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.23B | 113.8x | -2.41 | $58.80 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.9% Upside | Upgrade to Pro+ | |
| Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | $9.01B | -62.8x | 0.04 | $182.76 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.8% Upside | Upgrade to Pro+ | |
| Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.88B | -34.7x | -0.43 | $54.70 | 10.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.3% Upside | Upgrade to Pro+ | |
| Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.74B | -10.8x | 0.24 | $60.82 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.71B | 15.2x | -0.85 | $113.80 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.3% Upside | Upgrade to Pro+ | |
| Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | $8.63B | 20.5x | 0.05 | $41.71 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.1% Upside | Upgrade to Pro+ | |
| Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.22B | -17.8x | 0.4 | $104.62 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.3% Upside | Upgrade to Pro+ | |
| Cytokinetics Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.01B | -10x | 0.43 | $65 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.9% Upside | Upgrade to Pro+ | |
| Immunitybio Inc | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.75B | -19.5x | -0.58 | $7.47 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Kymera | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.23B | -24x | 0.99 | $88.37 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.5% Upside | Upgrade to Pro+ | |
| Belite Bio ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.76B | -74.7x | 0.92 | $168.51 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.4% Upside | Upgrade to Pro+ | |
| Arcellx | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.74B | -28.1x | 0.29 | $115.05 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.1% Upside | Upgrade to Pro+ | |
| Protagonist Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.69B | -50.9x | 0.34 | $104.58 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.6% Upside | Upgrade to Pro+ | |
| Apogee Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.53B | -17.1x | 0.9 | $88.04 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.4% Upside | Upgrade to Pro+ | |
| Centessa Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.12B | -27.1x | -1.06 | $39.52 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
| Terns Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.09B | -51.1x | -8.32 | $52.72 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.6% Upside | Upgrade to Pro+ | |
| Celcuity | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.82B | -31.6x | 1 | $120.60 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.4% Upside | Upgrade to Pro+ | |
| Cogent Biosciences | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.80B | -14.1x | $35.94 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| CG Oncology | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.68B | 0.76 | $67.03 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | ||
| Erasca | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.67B | -41.3x | -1.22 | $18.29 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12% Upside | Upgrade to Pro+ | |
| Scholar Rock | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.67B | -14.2x | 0.46 | $49.32 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.1% Upside | Upgrade to Pro+ | |
| Xenon Pharmaceuticals | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.64B | -13.5x | 0.36 | $58.92 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 34.8% Upside | Upgrade to Pro+ | |
| Alkermes Plc | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.53B | 23.2x | -0.69 | $33.20 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.5% Upside | Upgrade to Pro+ | |
| Immunovant | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.43B | -10x | 4.71 | $26.68 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Crispr Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.43B | -8.8x | 0.19 | $56.57 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.7% Upside | Upgrade to Pro+ | |
| Spyre Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.25B | -33.7x | -1.05 | $66.85 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.1% Upside | Upgrade to Pro+ | |
| Dianthus Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.01B | -22.5x | 0.45 | $95.04 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.8% Upside | Upgrade to Pro+ | |
| Amicus | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.54B | -164.5x | -3.2 | $14.45 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.3% Upside | Upgrade to Pro+ | |
| PureTech Health | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.19B | 85.5x | 0.05 | $17.23 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Crinetics Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $4.13B | -8x | 0.26 | $39.42 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |